849643-01-2

Upstream product

• 238755-38-9 6,7-dihydro-8(5H)-quinolinone-2-carboxaldehyde 
• 676-58-4 methylmagnesium chloride 
• 129337-86-6 2-chloro-5,6,7,8-tetrahydroquinolin-8-one 
• 6469-82-5 2-methyl-5,6,7,8-tetrahydroquinolin-8-ol 

Downstream Products

• 1369217-23-1 2,6-dimethyl-N-(2-methyl-5,6,7-trihydroquinolin-8-ylidene)phenylaminonickel(II) dichloride 
• 1369217-26-4 2,4,6-trimethyl-N-(2-methyl-5,6,7-trihydroquinolin-8-ylidene)phenylaminonickel(II) dichloride 
• 1369217-27-5 2,6-diethyl-4-methyl-N-(2-methyl-5,6,7-trihydroquinolin-8-ylidene)phenylaminonickel(II) dichloride 
• 1369217-24-2 2,6-diethyl-N-(2-methyl-5,6,7-trihydroquinolin-8-ylidene)phenylaminonickel(II) dichloride 
• 1369217-25-3 2,6-diisopropyl-N-(2-methyl-5,6,7-trihydroquinolin-8-ylidene)phenylaminonickel(II) dichloride 

Relevant academic research and scientific papers

Highly bulky and stable geometry-constrained iminopyridines: Synthesis, structure and application in Pd-catalyzed Suzuki coupling of aryl chlorides

A series of bulky geometry-constrained iminopyridylpalladium chlorides were developed. The steric environment adjacent to the nitrogen atom in the pyridine rings and diimine parts enhanced the thermal stability of the palladium species. Bulkier groups at the imino group stabilized the palladium species and the corresponding palladium chlorides showed high activities in the coupling reaction of aryl chlorides.

TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS

Disclosed herein are compounds that may be negative allosteric modulators of metabotropic receptors-subtype 5, and methods of making and using same.

4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same

The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.